GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Psyence Group Inc (XCNQ:PSYG) » Definitions » EBITDA Margin %

Psyence Group (XCNQ:PSYG) EBITDA Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Psyence Group EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Psyence Group's EBITDA for the three months ended in Dec. 2024 was C$-3.01 Mil. Psyence Group's Revenue for the three months ended in Dec. 2024 was C$0.00 Mil. Therefore, Psyence Group's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.


Psyence Group EBITDA Margin % Historical Data

The historical data trend for Psyence Group's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Group EBITDA Margin % Chart

Psyence Group Annual Data
Trend Dec19 Dec20 Mar22 Mar23 Mar24
EBITDA Margin %
- - - - -

Psyence Group Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Psyence Group's EBITDA Margin %

For the Drug Manufacturers - General subindustry, Psyence Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psyence Group's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Psyence Group's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Psyence Group's EBITDA Margin % falls into.


;
;

Psyence Group EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Psyence Group's EBITDA Margin % for the fiscal year that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=-69.275/0
= %

Psyence Group's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-3.01/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Psyence Group  (XCNQ:PSYG) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Psyence Group EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Psyence Group's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Psyence Group Business Description

Traded in Other Exchanges
Address
121 Richmond Street West, Penthouse Suite, 1300, Toronto, ON, CAN, M5H 2K1
Psyence Group Inc is a life science biotechnology company focused on the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness.
Executives
Jody Aufrichtig Director, Senior Officer
Warwick Corden-lloyd Senior Officer
Neil Maresky Senior Officer

Psyence Group Headlines

No Headlines